Publications

Clinical Trials - ABSTRACTS

1. Huntington Study Group (Marshall FJ, primary author). Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Mov Disord 1996;11:59.
2. Huntington Study Group (K Kieburtz, presenter). Placebo-Controlled Trial of Creatine in Huntington’s Disease. Neurol 2001;56:A386.
3. Huntington Study Group (FJ Marshall, presenter). Riluzole dosing in Huntington's Disease (RID-HD): Results of an 8-week double-blind, placebo-controlled, multi-center study by the Huntington Study Group. Proceedings of the 19th International Meeting of the World Federation of Neurology Research Group on Huntington’s Disease, August 25-28, 2001, Copenhagen, Denmark. Publ-ication of the Panum Institute, p. 29-30, 2001.
4. Huntington Study Group (M. Cudkowicz, primary author). Minocycline safety and tolerability in Huntington’s disease. Mov Disord 2003;18:1084.
5. Frank SA, Marshall F, Plumb S, Oakes D, Shoulson I, Kieburtz K, CARE-HD Investigators of the Huntington Study Group. Functional decline due to chorea in Huntington’s disease. Neurol 2004;62(Suppl 5):A204.
6. Huntington Study Group (F.J. Marshall, presenter). A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine in Patients with Huntington’s Disease. Mov Disord 2004;19:1122.
7. Frank S, Ondo W, Hunter C, Marshall F, Walker F, Eberly S, Factor S, Fahn S, Hunt V, Oakes D, Plumb S, Shinaman A, Shoulson I, Zhao H, Jankovic J. A randomized, double-blind, placebo-controlled, staggered withdrawal study in patients with Huntington’s disease treated with tetrabenazine. Mov Disord 2005;20(9):1244.
8. Hyson, C. for the Huntington Study Group. Pre-2CARE: a dosage ranging trial of coenzyme Q10 in Huntington’s Disease and in healthy subjects. Hereditary Diseases Foundation Annual Symposium, August 2004.
9. Hyson HC & the Huntington Study Group, QuBE: A bioequivalence study of coenzyme Q10 in healthy subjects. Movement Disorders Society Meeting. 2005.
10. Marshall FJ, Eberly S, Frank S, Oakes D and the Huntington Study Group/TETRA-HD Investigators. Predictors of response to tetrabenazine in Huntington’s disease. Mov Disord 2006;21(9):1547.
11. Frank SA on behalf of the Huntington Study Group TETRA-HD Investigators. An open label study of tetrabenazine as anti-chorea therapy in Huntington disease. Neuro 2007;68(Suppl 1):A365.